Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

First Posted Date
2022-07-07
Last Posted Date
2024-12-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
160
Registration Number
NCT05446870
Locations
🇨🇳

Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan

🇪🇸

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain

🇪🇸

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain

and more 42 locations

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

First Posted Date
2022-06-30
Last Posted Date
2022-06-30
Lead Sponsor
Fudan University
Target Recruit Count
70
Registration Number
NCT05438706
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

First Posted Date
2022-06-23
Last Posted Date
2022-12-14
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
250
Registration Number
NCT05429463
Locations
🇨🇳

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

First Posted Date
2022-06-22
Last Posted Date
2024-10-30
Lead Sponsor
Caigang Liu
Target Recruit Count
136
Registration Number
NCT05426486
Locations
🇨🇳

Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

First Posted Date
2022-06-15
Last Posted Date
2024-12-05
Lead Sponsor
University of Chicago
Target Recruit Count
30
Registration Number
NCT05420948
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

A Study for the Adjuvant Treatment of Breast Cancer

First Posted Date
2022-06-15
Last Posted Date
2022-07-01
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
2413
Registration Number
NCT05420467
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Study for the Neoadjuvant Treatment of Breast Cancer

First Posted Date
2022-06-15
Last Posted Date
2022-07-01
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
1576
Registration Number
NCT05420454
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

First Posted Date
2022-06-13
Last Posted Date
2023-11-18
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
45
Registration Number
NCT05415709
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

First Posted Date
2022-06-08
Last Posted Date
2024-12-27
Lead Sponsor
D3 Bio (Wuxi) Co., Ltd
Target Recruit Count
392
Registration Number
NCT05410145
Locations
🇪🇸

D3 Bio Investigative Site, Valencia, Spain

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

First Posted Date
2022-06-03
Last Posted Date
2024-06-24
Lead Sponsor
iTeos Belgium SA
Target Recruit Count
186
Registration Number
NCT05403385
Locations
🇺🇸

Highlands Oncology Group, Fayetteville, Arkansas, United States

🇺🇸

Innovative Clinical Research Institute (ICRI), Whittier, California, United States

🇺🇸

Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States

and more 64 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy